Immunomodulators for the treatment of Crohn’s disease in adults: optimal use and prospects for future drug treatments - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Expert Review of Clinical Immunology Année : 2016

Immunomodulators for the treatment of Crohn’s disease in adults: optimal use and prospects for future drug treatments

Résumé

Crohn's disease (CD) requires treatment beyond symptoms by enabling and maintaining mucosal healing and therefore clinical remission. However, with the increasing use of biologics there have been safety concerns and there is a significant cost implication with the early use of biologics. Therefore, it is imperative that patients with severe/complicated disease or poor prognostic factors are treated with an aggressive strategy while all remaining patients should be treated in a step-up strategy. The potential for disease modification with thiopurines and methotrexate is debated in CD when they are used as a monotherapy. In this review we discuss existing and newer therapies that have recently been developed for CD. We will also provide an algorithm for current management of adult CD patients in routine clinical practice.
Fichier non déposé

Dates et versions

hal-01662854 , version 1 (13-12-2017)

Identifiants

Citer

Patrick Allen, Laurent Peyrin-Biroulet. Immunomodulators for the treatment of Crohn’s disease in adults: optimal use and prospects for future drug treatments. Expert Review of Clinical Immunology, 2016, 12 (7), pp.741 - 749. ⟨10.1586/1744666X.2016.1154789⟩. ⟨hal-01662854⟩
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More